Search Results

Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Bruker Corporation announced it will present at the following conferences.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.

Humanetics Corporation is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization International Convention in San Diego, CA next week.

Pulmatrix, Inc. announced a series of transactions with MannKind Corporation.